Dyslipidaemia in Type 1 Diabetes: Molecular Mechanisms and Therapeutic Opportunities

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2021 Aug 6

PMID 34356890

Citations 4

Authors

Stephen T OBrien

Orla M Neylon

Timothy OBrien

Affiliations

Soon will be listed here.

Abstract

Cardiovascular disease (CVD) is the leading cause of death in Type 1 Diabetes (T1D). The molecular basis for atherosclerosis in T1D is heavily influenced by hyperglycaemia and its atherogenic effects on LDL. Ongoing research into the distinct pathophysiology of atherosclerosis in T1D offers exciting opportunities for novel approaches to calculate CVD risk in patients with T1D and to manage this risk appropriately. Currently, despite the increased risk of CVD in the T1D population, there are few tools available for estimating the risk of CVD in younger patients. This poses significant challenges for clinicians in selecting which patients might benefit from lipid-lowering therapies over the long term. The current best practice guidance for the management of dyslipidaemia in T1D is generally based on evidence from patients with T2D and the opinion of experts in the field. In this review article, we explore the unique pathophysiology of atherosclerosis in T1D, with a specific focus on hyperglycaemia-induced damage and atherogenic LDL modifications. We also discuss the current clinical situation of managing these patients across paediatric and adult populations, focusing on the difficulties posed by a lack of strong evidence and various barriers to treatment.

Citing Articles

Association of glycemic variability and time in range with lipid profile in type 1 diabetes.

Salsa-Castelo M, Neves C, Neves J, Carvalho D Endocrine. 2023; 83(1):69-76.

PMID: 38051418 PMC: 10805887. DOI: 10.1007/s12020-023-03464-x.

Nuclear Magnetic Resonance-Based Lipidomics in the Assessment of Cardiometabolic Risk in Type 1 Diabetes: An Exploratory Analysis.

Seres-Noriega T, Ortega E, Perea V, Gimenez M, Boswell L, Mariaca K Diabetes Ther. 2023; 14(3):553-567.

PMID: 36732434 PMC: 9981843. DOI: 10.1007/s13300-023-01372-x.

Mediterranean Diet and Its Association with Cardiovascular Disease Risk Factors: A Scoping Review.

Richardson L, Izuora K, Basu A Int J Environ Res Public Health. 2022; 19(19).

PMID: 36232062 PMC: 9566634. DOI: 10.3390/ijerph191912762.

Lipids and Lipoproteins in Health and Disease.

Bezsonov E, Sobenin I, Orekhov A Biomedicines. 2022; 10(1).

PMID: 35052767 PMC: 8773467. DOI: 10.3390/biomedicines10010087.

References

Retnakaran R, Zinman B . Type 1 diabetes, hyperglycaemia, and the heart. Lancet. 2008; 371(9626):1790-9. DOI: 10.1016/S0140-6736(08)60767-9. View

Beckman J, Creager M, Libby P . Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002; 287(19):2570-81. DOI: 10.1001/jama.287.19.2570. View

Guo V, Cao B, Wu X, Lee J, Zee B . Prospective Association between Diabetic Retinopathy and Cardiovascular Disease-A Systematic Review and Meta-analysis of Cohort Studies. J Stroke Cerebrovasc Dis. 2016; 25(7):1688-1695. DOI: 10.1016/j.jstrokecerebrovasdis.2016.03.009. View

Zhang Y, Jenkins A, Basu A, Stoner J, Lopes-Virella M, Klein R . Associations between intensive diabetes therapy and NMR-determined lipoprotein subclass profiles in type 1 diabetes. J Lipid Res. 2015; 57(2):310-7. PMC: 4727426. DOI: 10.1194/jlr.P060657. View

Fuchs T, Abed U, Goosmann C, Hurwitz R, Schulze I, Wahn V . Novel cell death program leads to neutrophil extracellular traps. J Cell Biol. 2007; 176(2):231-41. PMC: 2063942. DOI: 10.1083/jcb.200606027. View

Poznyak A, Grechko A, Poggio P, Myasoedova V, Alfieri V, Orekhov A . The Diabetes Mellitus-Atherosclerosis Connection: The Role of Lipid and Glucose Metabolism and Chronic Inflammation. Int J Mol Sci. 2020; 21(5). PMC: 7084712. DOI: 10.3390/ijms21051835. View

Jensen M, Sogaard P, Gustafsson I, Bech J, Hansen T, Almdal T . Echocardiography improves prediction of major adverse cardiovascular events in a population with type 1 diabetes and without known heart disease: the Thousand & 1 Study. Diabetologia. 2019; 62(12):2354-2364. DOI: 10.1007/s00125-019-05009-2. View

Margeirsdottir H, Larsen J, Brunborg C, Overby N, Dahl-Jorgensen K . High prevalence of cardiovascular risk factors in children and adolescents with type 1 diabetes: a population-based study. Diabetologia. 2008; 51(4):554-61. DOI: 10.1007/s00125-007-0921-8. View

Sever P, Poulter N, Dahlof B, Wedel H, Collins R, Beevers G . Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care. 2005; 28(5):1151-7. DOI: 10.2337/diacare.28.5.1151. View

10.

Berenson G, Wattigney W, Tracy R, Newman 3rd W, Srinivasan S, Webber L . Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (The Bogalusa Heart Study). Am J Cardiol. 1992; 70(9):851-8. DOI: 10.1016/0002-9149(92)90726-f. View

11.

Amor A, Catalan M, Perez A, Herreras Z, Pinyol M, Sala-Vila A . Nuclear magnetic resonance lipoprotein abnormalities in newly-diagnosed type 2 diabetes and their association with preclinical carotid atherosclerosis. Atherosclerosis. 2016; 247:161-9. DOI: 10.1016/j.atherosclerosis.2016.02.014. View

12.

Marcovecchio M, Dalton R, Prevost A, Acerini C, Barrett T, Cooper J . Prevalence of abnormal lipid profiles and the relationship with the development of microalbuminuria in adolescents with type 1 diabetes. Diabetes Care. 2009; 32(4):658-63. PMC: 2660471. DOI: 10.2337/dc08-1641. View

13.

Maahs D, Dabelea D, DAgostino Jr R, Andrews J, Shah A, Crimmins N . Glucose control predicts 2-year change in lipid profile in youth with type 1 diabetes. J Pediatr. 2012; 162(1):101-7.e1. PMC: 3807690. DOI: 10.1016/j.jpeds.2012.06.006. View

14.

Amor A, Castelblanco E, Hernandez M, Gimenez M, Granado-Casas M, Blanco J . Advanced lipoprotein profile disturbances in type 1 diabetes mellitus: a focus on LDL particles. Cardiovasc Diabetol. 2020; 19(1):126. PMC: 7416413. DOI: 10.1186/s12933-020-01099-0. View

15.

Rosen P, Nawroth P, King G, Moller W, Tritschler H, Packer L . The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev. 2001; 17(3):189-212. DOI: 10.1002/dmrr.196. View

16.

de Ferranti S, de Boer I, Fonseca V, Fox C, Golden S, Lavie C . Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Circulation. 2014; 130(13):1110-30. DOI: 10.1161/CIR.0000000000000034. View

17.

Lyons T, Jenkins A, Zheng D, Klein R, Otvos J, Yu Y . Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-media thickness. Diabet Med. 2006; 23(9):955-66. DOI: 10.1111/j.1464-5491.2006.01905.x. View

18.

Steinberg D, Bennett G, Svetkey L . The DASH Diet, 20 Years Later. JAMA. 2017; 317(15):1529-1530. PMC: 5509411. DOI: 10.1001/jama.2017.1628. View

19.

Rawshani A, Rawshani A, Franzen S, Eliasson B, Svensson A, Miftaraj M . Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. N Engl J Med. 2017; 376(15):1407-1418. DOI: 10.1056/NEJMoa1608664. View

20.

Summerhill V, Grechko A, Yet S, Sobenin I, Orekhov A . The Atherogenic Role of Circulating Modified Lipids in Atherosclerosis. Int J Mol Sci. 2019; 20(14). PMC: 6678182. DOI: 10.3390/ijms20143561. View